atevirdine
Small moleculeexperimental
Atevirdine is a non-nucleoside reverse transcriptase inhibitor that has been studied for the treatment of HIV. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002094)
Timeline
Indications
Studied for
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1- Mol. weight
- 379.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAtevirdine ↗
- ChEMBLCHEMBL280527 ↗
Also known as
- atevirdine
- atevirdine
- atevirdine
- atevirdine
- atevirdine mesylate
- atevirdine mesylate
- atevirdine mesylate
- atevirdine mesylate
- piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1h-indol-2-yl)carbonyl)-
- u 87201
- u-87201
- u-87201
- u-87201
- u 87201e
- u-87201e
- u-87201e
- u-87201e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000742 | Phase 1 | Nov 2, 1999 | Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID), Upjohn |
| NCT00000753 | Phase 1 | Nov 2, 1999 | Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID), Upjohn |
| NCT00002094 | N/A | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002322 | Phase 2 | Nov 2, 1999 | Pharmacia & Upjohn |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glaxo Wellcome | For profit | 2 | 0 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 1999 |
| Pharmacia & Upjohn | For profit | 2 | 2 | 2 | 1999 |
| Upjohn | For profit | 2 | 0 | 1 | 1999 |
4 organizations
Page 1 / 1